Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02255565 · ClinicalTrials.gov registry record · Phase 4
Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
A Phase 4 study, sponsored by Seattle Children's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
NCT02255565: Completed Phase 4 study, sponsored by Seattle Children's Hospital.
NCT02255565 is a Phase 4 study that has completed, run by Seattle Children's Hospital. The registered enrollment target is 36 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02255565, a Phase 4 study, has completed, sponsored by Seattle Children's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Quillivant XR is effective in the treatment of ADHD in children with Autism Spectrum Disorder (ASD).
Primary Outcome
Measures the severity of Total ADHD symptoms, Inattention and Hyperactivity/Impulsive symptoms. The Inattention and Hyperactivity/Impulsive symptoms can range from 0 to 27 each, with a higher score reflecting more severe ADHD symptoms. The total score is calculated by summing the inattention and Hyperactivity/Impulsive subscales. The total score can range from 0 to 54 with a higher score reflecting more severe ADHD symptoms.
Interventions
- DRUG Very Low Dose Quillivant XR
- DRUG Low Dose Quillivant XR
- DRUG Moderate Dose Quillivant XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-10 |
| Phase | Phase 4 |
What the finished NCT02255565 record still lists
NCT02255565 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 3 interventions - of which Very Low Dose Quillivant XR is the first listed.
NCT02255565 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02255565 about?
NCT02255565 is a clinical study titled "Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study". The purpose of this study is to determine whether Quillivant XR is effective in the treatment of ADHD in children with Autism Spectrum Disorder (ASD).
What is the current status of trial NCT02255565?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2014-09. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02255565?
The interventions under investigation include: Very Low Dose Quillivant XR (DRUG), Low Dose Quillivant XR (DRUG), Moderate Dose Quillivant XR (DRUG).
Who is sponsoring clinical trial NCT02255565?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02255565's enrollment target sits among peer trials
36 1490th of 2000 higher than 495 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia